



# Around the world of US healthcare in 360 words or less



April 27, 2026 | Issue 414

## Editor's note

*[This series](#) is produced by KPMG Healthcare and is intended to be short and succinct, less than 360 words, to provide a weekly digestible bite of healthcare regulatory, policy, and industry news relevant to our clients. Links are provided to source material (proposed and final regulations, agency guidance and press releases, reports, research, etc.) when available. Please share this email with colleagues and other interested individuals, and encourage them to [subscribe to our mailing list here](#).*

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

[Subscribe here](#)



## Healthcare regulatory news

CMS and FDA announced [Regulatory Alignment for Predictable and Immediate Device \(RAPID\)](#), a new coverage pathway for medical devices. The initiative aims to accelerate Medicare coverage for certain FDA-designated Class II and Class III Breakthrough Devices by aligning regulatory and coverage expectations earlier in the process. The

agency also noted it will pause accepting new candidates for the [Transitional Coverage for Emerging Technologies \(TCET\) Pathway](#).

The Trump administration [delayed](#) the launch of its GLP-1 access model ([BALANCE](#)) for Medicare Part D following [insurers' concerns](#) about market instability and insufficient utilization data. CMS is extending a risk-free "bridge" program through 2027 to maintain Medicare beneficiary access to GLP-1s while it attempts to address industry concerns.

CMS Administrator Dr. Mehmet Oz [announced](#) that the agency will require all 50 states to [revalidate](#) Medicaid providers in "high-risk" areas, specifically targeting those without National Provider Identifiers. States must submit a comprehensive revalidation strategy within 30 days and provide a notice of intent and timeline within 10 days.

President Trump [issued](#) an executive order [designed](#) to accelerate the development of and patient access to psychedelic drugs for serious, treatment-resistant mental illnesses. The directive grants priority vouchers for qualifying drugs, directs FDA and DEA to establish patient access pathways under the [Right to Try Act](#), and allocates \$50M for state-level support.

HHS is [seeking nominations](#) for new U.S. Preventive Services Task Force members, the independent panel that determines which preventive services must be fully covered by insurers. Secretary Kennedy has repeatedly [expressed interest](#) in overhauling the panel to include a broader range of clinicians.



## Healthcare law and policy news

Some House Democrats are [urging](#) the Employee Benefits Security Administration to broaden its PBM [proposed rule](#) by expanding transparency requirements to include fully insured plans and third-party administrators. While the lawmakers acknowledged progress toward mandating compensation disclosures, they called for further action to mitigate costs.

A [JAMA study](#) found an 11% reduction in suicide deaths among individuals aged 15 to 34 relative to projections following the 2022 implementation of the 988 crisis hotline. The analysis identifies a correlation between increased state-level call volumes and larger

declines in suicide mortality, [suggesting](#) the revamped lifeline's supportive role in mitigating youth mental health crises.



Please send your questions or comments to [us-hclspractice@kpmg.com](mailto:us-hclspractice@kpmg.com).

## KPMG. Make the Difference.

Learn about us:



[kpmg.com](https://kpmg.com)



Subscribe

Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.

[Privacy](#) | [Legal](#)

You have received this message from KPMG LLP. If you wish to unsubscribe from this publication or from other KPMG communications, please click [here](#) to visit your KPMG Communication Preferences Center. To unsubscribe from all KPMG communications, click [here](#).

© 2026 KPMG LLP, a Delaware limited liability partnership, and its subsidiaries are part of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.

USCS035556-1A